Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Kaye

Showing results (751-760 of 853) with videos related to

Pageof 86
Sort By:
International Journal of Andrology|February 1, 1987
Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III studyG Stoter, R Sylvester, D T Sleijfer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)R L Jansen, R Sylvester, D T Sleyfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1986
High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative GroupG Stoter, D T Sleyfer, W W ten Bokkel Huinink, et al.
Oncology|August 15, 2012
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trialsB Basu, J Vitfell-Pedersen, V Moreno Garcia, et al.
British Journal of Cancer|November 21, 1998
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significanceR de Wit, L Collette, R Sylvester, et al.
British Journal of Cancer|January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumoursK H Khan, T A Yap, A Ring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatmentViviane Hess, Roger A'Hern, Nazar Nasiri, et al.
Molecular Cancer Therapeutics|January 11, 2011
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2Siân Rizzo, Jenny M Hersey, Paul Mellor, et al.
The British Journal of Ophthalmology|October 10, 2025
Antimicrobial concentrations in the cornea and aqueous humour: a meta-analysisKeri McLean, Grace Dawson, Daniel Foulkes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trialsDavid Olmos, Richard D Baird, Timothy A Yap, et al.
Pageof 86

Showing results (751-760 of 853) with videos related to

Sort By:
Pageof 86
International Journal of Andrology|February 1, 1987
Multivariate analysis of prognostic variables in patients with disseminated non-seminomatous testicular cancer: results from an EORTC multi-institutional phase III studyG Stoter, R Sylvester, D T Sleijfer, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1991
Long-term follow-up of non-seminomatous testicular cancer patients with mature teratoma or carcinoma at postchemotherapy surgery. EORTC Genitourinary Tract Cancer Cooperative Group (EORTC GU Group)R L Jansen, R Sylvester, D T Sleyfer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1986
High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative GroupG Stoter, D T Sleyfer, W W ten Bokkel Huinink, et al.
Oncology|August 15, 2012
Creatinine clearance is associated with toxicity from molecularly targeted agents in phase I trialsB Basu, J Vitfell-Pedersen, V Moreno Garcia, et al.
British Journal of Cancer|November 21, 1998
Serum alpha-fetoprotein surge after the initiation of chemotherapy for non-seminomatous testicular cancer has an adverse prognostic significanceR de Wit, L Collette, R Sylvester, et al.
British Journal of Cancer|January 13, 2016
Phase I trial outcomes in older patients with advanced solid tumoursK H Khan, T A Yap, A Ring, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Mucinous epithelial ovarian cancer: a separate entity requiring specific treatmentViviane Hess, Roger A'Hern, Nazar Nasiri, et al.
Molecular Cancer Therapeutics|January 11, 2011
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2Siân Rizzo, Jenny M Hersey, Paul Mellor, et al.
The British Journal of Ophthalmology|October 10, 2025
Antimicrobial concentrations in the cornea and aqueous humour: a meta-analysisKeri McLean, Grace Dawson, Daniel Foulkes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 3, 2011
Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trialsDavid Olmos, Richard D Baird, Timothy A Yap, et al.
Pageof 86